Clinical Science  |   February 1996
Residual Block after Mivacurium with or without Edrophonium Reversal in Adults and Children
Author Notes
  • (D. Bevan) Professor.
  • (Kahwaji, Ansermino) Clinical/Research Fellow.
  • (Reimer) Clinical Instructor.
  • (Smith) Clinical Assistant Professor.
  • (O'Connor) Clinical Associate Professor.
  • (J. Bevan) Associate Professor
  • Received from the Departments of Anaesthesia, Vancouver Hospital and Health Sciences Centre and British Columbia's Children's Hospital, and the University of British Columbia. Submitted for publication May 19, 1995. Accepted for publication November 8, 1995. Supported in part by a grant from Burroughs Wellcome Inc. Presented at the meeting of the Canadian Anaesthetists Society, Ottawa, Ontario, Canada, June 24-27, 1995.
  • Address correspondence to Dr. D. Bevan: Department of Anaesthesia, 3rd floor, 910 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E3. Address electronic mail to:
Article Information
Clinical Science
Clinical Science   |   February 1996
Residual Block after Mivacurium with or without Edrophonium Reversal in Adults and Children
Anesthesiology 2 1996, Vol.84, 362-367.. doi:
Anesthesiology 2 1996, Vol.84, 362-367.. doi:
Key words: Anesthesia: adult; pediatric. Antagonists, neuromuscular relaxant: edrophonium. Complications: residual neuromuscular blockade. Neuromuscular relaxants: mivacurium.
THE major difference between mivacurium and other nondepolarizing relaxants is the rapid spontaneous recovery of neuromuscular activity after its use. In adults, the recovery index (RI; time from 25% to 75% recovery of adductor pollicis twitch tension in response to ulnar nerve stimulation) is 6-8 min, [1] compared with 11-14 min for atracurium [2] and vecuronium [3] and 25-40 min for pancuronium, [4] pipecuronium, [5] or doxacurium. [6] In children, the RI for mivacurium is 4-6 min, [7] which is less than that for atracurium, [8] vecuronium, [9] or pancuronium. [10] It has been suggested that the rate of spontaneous recovery is so rapid that reversal of the block rarely is necessary. [11] If this could be substantiated, the hemodynamic [12] and intestinal [13] side effects of anticholinesterases could be avoided. Ding et al. have shown that, when anticholinesterases are avoided after the use of mivacurium in laparoscopic surgery, the incidence of postoperative nausea and vomiting is reduced. [14] .
It is recognized that one of the most serious postanesthetic complications is ventilatory inadequacy as a result of residual neuromuscular blockade. [15] It has been shown previously in adults that the incidence of residual block, defined as a train-of-four (TOF) ratio of < 0.7, occurs in 30-40% of patients after anesthesia when long-acting relaxants, such as pancuronium or d-tubocurarine, have been administered. This occurs despite the use of clinical neuromuscular monitoring during surgery and after the administration of reversal agents, [15,16] but this incidence can be reduced if atracurium or vecuronium is substituted for long-acting agents. [17] In children, the incidence of residual block is much reduced [18] but may occur. [19] Thus, before omission of pharmacologic reversal of mivacurium neuromuscular block can be recommended with confidence, it is important to demonstrate that such a practice will not result in residual neuromuscular block.
The purpose of this study was to determine whether avoidance of reversal of neuromuscular block after mivacurium was associated with residual block. Mivacurium was administered to adults and children by infusion to maintain an intense level of neuromuscular block during nitrous oxide/fentanyl/propofol anesthesia. At the end of surgery, the infusion was stopped, and in half the patients in each age group, the block was reversed with edrophonium and atropine. The presence of residual block when the patients arrived in the postanesthesia care unit (PACU) was detected by clinical evaluation and electromyography.
After institutional approval and written, informed consent from the patient or parent, 50 adults (20-60 yr) and 50 children (2-12 yr) were studied. All were ASA physical status 1 or 2 and free of neurologic, respiratory, renal, or hepatic disease and were not receiving drugs that could interfere with normal neuromuscular function. They were scheduled for elective surgical procedures with anticipated durations of at least 1 h.
Premedication was at the discretion of the anesthesiologist, and pediatric patients had local anesthetic cream (EMLA) applied to the dorsum of the hand preoperatively to facilitate intravenous cannulation. Anesthesia was induced with propofol (1.5-3 mg *symbol* kg sup -1 in adults and 5 mg *symbol* kg sup -1 in children), 0.3 mg *symbol* kg sup -1 lidocaine, and 1-2 micro gram *symbol* kg sup -1 fentanyl intravenously. Blood was sampled before administration of mivacurium for estimation of plasma cholinesterase activity and dibucaine number. Tracheal intubation was facilitated with 0.2 mg *symbol* kg sup -1 intravenous mivacurium, and an infusion of mivacurium was commenced as soon as a twitch response of the thumb was elicited by TOF stimulation of the ulnar nerve using a Dualstim III Nerve Stimulator (Lifetech, Houston, TX) or other clinical peripheral nerve stimulator. The initial infusion rates were 10 micro gram *symbol* kg sup -1 *symbol* min sup -1 in adults and 20 micro gram *symbol* kg sup -1 min sup -1 in children. Adjustments to the rate were made at 2-5-min intervals to maintain a level of neuromuscular blockade at which one or two twitch responses to TOF stimulation were visible. Anesthesia was maintained with oxygen and nitrous oxide inhalation and an infusion of propofol (50-300 micro gram *symbol* kg sup -1 *symbol* min sup -1). Incremental doses of fentanyl were given, and the propofol infusion titrated to provide satisfactory levels of anesthesia, which maintained cardiovascular stability without the addition of volatile anesthetic agents.
The mivacurium infusion was stopped at the end of surgery, and spontaneous recovery of neuromuscular blockade was allowed to proceed for 10 min. The patients in both of the age groups were randomized to receive 0.5 mg *symbol* kg sup -1 edrophonium with 0.02 mg *symbol* kg sup -1 atropine or saline for reversal of residual neuromuscular blockade. The reversal agent and placebo were identical in appearance and made up to standard volumes, so that the anesthesiologist who administered the drugs was unaware of the randomization choice. The anesthesiologist in charge of the patient decided on the times for tracheal extubation and transfer of the patient to the recovery room, based solely on clinical criteria, which might include use of a peripheral nerve stimulator. Further doses of edrophonium and atropine could be administered at any time if considered necessary on clinical grounds. On arrival in the recovery room, neuromuscular monitoring was performed using a Puritan Bennett Datex Relaxograph (Helsinki, Finland) to record three consecutive responses of the electromyographic response of the adductor pollicis to TOF supramaximal stimulation of the ulnar nerve at 10-s intervals. The electromyogram was used in the uncalibrated mode to obtain TOF ratios only. The arm free of the intravenous infusion was selected for monitoring, and skin temperature over the adductor pollicis at the recording site was measured and maintained above 32 degrees C by use of warming blankets.
The duration of anesthesia and the total dose of mivacurium administered were noted. Time from the administration of edrophonium or saline to the beginning of electromyogram monitoring in the recovery room was recorded. The three TOF ratios measured were averaged for statistical analysis. Data were expressed as mean+/-SD. In each age group, comparisons were made between the TOF ratios on arrival in the recovery room after edrophonium or saline using Student's t-test and the incidence of postoperative residual blockade, clinical weakness, or TOF ratio less or equal to 0.7 in the adults and children was compared using Fisher's exact text. Values of P < 0.05 were considered to show significant differences.
Adults Versus Children
The mean ages were 4.5+/-2.2 and 37.6+/-9.2 yr, and the mean weights were 19.2+/-8.0 and 66.0+/-13.1 kg, of children and adults, respectively. The duration of neuromuscular block was similar in adults and children, 66.0+/-13.1 versus 73.3 +/-30.4 min, but the mivacurium infusion rate required to maintain constant block was greater in children, 0.017+/-0.005 versus 0.006+/-0.003 mg *symbol* kg sup -1 *symbol* min sup -1, and the time interval from reversal to assessment in the PACU was longer in adults, 12.9+/-5.3 versus 8.2+/-3.4 min (P < 0.01). Plasma cholinesterase activity was greater in children than in adults, 8.8 +/-1.6 versus 7.0+/-2.1 kU/l (P < 0.01).
The mean ages and weights and sex distribution were similar in the reversal and saline groups (Table 1). The duration of neuromuscular block was greater in patients who had received edrophonium (P < 0.01), but the infusion rate was similar (Table 2). The times from reversal to PACU assessment and the mean TOF ratios on assessment were similar in the saline-treated and edrophonium-treated patients. However, in the saline group, four had a TOF ratio < 0.7, and two others were so weak on arrival in the PACU (small tidal volume, inability to head-lift, weak hand-grip) that edrophonium was administered to restore ventilation and muscle tone before assessments could be made (Table 2). Thus, six of the saline-treated patients demonstrated residual neuromuscular block in the PACU compared with one patient in the edrophonium group who had a TOF ratio < 0.7 (P < 0.05). In five of these seven patients, recovery to TOF > 0.7 occurred spontaneously within 10 min, but two from the saline group required additional edrophonium before adequate recovery was achieved. The seven adults who demonstrated residual neuromuscular block did not appear to differ from their cohorts with respect to age, duration of infusion, mivacurium requirement, plasma cholinesterase activity, or in the times from reversal to assessment (Table 3).
Table 1. Demographic Data
Image not available
Table 1. Demographic Data
Table 2. Characteristics of Mivacurium Meeting Abstracts Related to Train-of-Four Ratio Measured on Arrival in the Postanesthesia Care Unit in Adults and Children*
Image not available
Table 2. Characteristics of Mivacurium Meeting Abstracts Related to Train-of-Four Ratio Measured on Arrival in the Postanesthesia Care Unit in Adults and Children*
Table 3. Characteristics of the Seven (14%) Adult Patients Who Demonstrated Residual Block (TOF < 0.7) on Arrival in the Postanesthesia Care Unit
Image not available
Table 3. Characteristics of the Seven (14%) Adult Patients Who Demonstrated Residual Block (TOF < 0.7) on Arrival in the Postanesthesia Care Unit
There were no significant differences in age, weight, sex distribution, duration of infusion, infusion dose, or time from reversal to PACU assessment between the saline- and edrophonium-treated children (Table 1). Although all had TOF > 0.7, the mean TOF ratio was less in the saline than in the edrophonium group (P < 0.01; Table 2).
This study demonstrated that, in adults, after an infusion of mivacurium sufficient to maintain intense neuromuscular block, 6 of 25 patients in whom reversal was not attempted at the end of anesthesia had residual block on arrival in the PACU. Only 1 of 25 patients in whom the block had been reversed with 0.5 mg *symbol* kg sup -1 edrophonium demonstrated residual block. None of the children who had received a neuromuscular block of similar intensity, half of whom had received edrophonium, demonstrated residual neuromuscular block, although the time from reversal of the block in the operating room to assessment in the PACU was less than in adults (P < 0.05), and a greater dose of mivacurium was required to maintain an equivalent degree of neuromuscular block. The incidences of residual block, clinical weakness, and/or TOF < 0.7, in the adult patients (24%) in whom the block was not reversed were similar to rates previously described in adults after reversal of a block produced by long-acting neuromuscular blocking drugs. [15-17] This suggests that failure to reverse mivacurium-induced block may lead to residual neuromuscular block. Avoidance of reversal should be limited to those patients in whom recovery from the block has been confirmed with neuromuscular monitoring.
In children, the risk of residual neuromuscular block is low. Previous studies have demonstrated that spontaneous recovery from neuromuscular block produced by several agents, including mivacurium, [1,6] occurs more rapidly in children than in adults. In addition, Meakin et al. demonstrated, using the same doses of edrophonium or neostigmine to reverse pancuronium-induced block, that more rapid recovery occurred in children than in adults. [20] Similarly, the dose of neostigmine [21] but not of edrophonium [22] required to antagonize d-tubocurarine-induced neuromuscular block was less in infants and children than in adults. In the latter reports, pharmacokinetic studies showed that the volumes of distribution of neostigmine and edrophonium were similar in all age groups, suggesting that the differences were not due to altered pharmacokinetic behavior. Also, in these studies, d-tubocurarine was administered by continuous infusion to maintain a constant level of neuromuscular block, rather than by bolus injection. Nevertheless, the comparisons between children and adults apply.
The overall recovery of neuromuscular activity after reversal results from spontaneous recovery and its acceleration by anticholinesterases. The more rapid rate of spontaneous recovery and the much greater mivacurium infusion requirement may result, at least in part, from greater plasma cholinesterase (pChe) activity in these children. In adults, it has been shown that the duration of mivacurium-induced neuromuscular blockade is inversely related to pChe [23] and is moderately prolonged in patients who are heterozygous for the usual and the atypical gene for pChe. [24] Recovery is greatly delayed in patients homozygous for the atypical gene. [24,25] Although some authors were unable to demonstrate age-related differences in pChe activity, [26] it is possible to recognize pChe variants using techniques of molecular genetics [27] so that previously unrecognized abnormalities of the enzyme can be identified.
The current study suffers from several of the problems associated with clinical investigations. Mivacurium was used to provide neuromuscular block for clinical indications. Anesthesia with propofol/fentanyl/nitrous oxide was chosen to prevent potentiation of the block and impairment of reversal by inhalational agents, [28] and the intensity of the block was maintained constant by appropriate monitoring and adjustment of the infusion rate. However, although the reversal agent, or saline, was given after some neuromuscular activity had been demonstrated 10 min earlier at the termination of the infusion, the interval from its administration and the subsequent arrival and assessment of neuromuscular activity in the PACU occasionally was delayed in adults. Thus, the assessment was made, as in clinical practice, at different times after reversal. Nevertheless, we believe the findings are applicable to clinical practice. It is interesting that the times from reversal to PACU assessment in the current study were similar to those found in previous investigations of residual neuromuscular block in adults [17] but were less than was previously documented in children. [18] Perhaps, if a longer time had elapsed from stopping the infusion until arrival in the PACU or if a less intense neuromuscular block had been produced, a greater degree of recovery would have been demonstrated in adults. However, in certain circumstances, such as after laparoscopic cholecystectomy, when surgery is terminated quickly, very rapid recovery from neuromuscular block is required.
We have shown that residual neuromuscular block may occur in adults if mivacurium-induced neuromuscular block is not reversed. We suggest that recovery, assessed by neuromuscular monitoring, be confirmed before reversal is omitted. Previous studies have demonstrated the effectiveness of both edrophonium and neostigmine in accelerating recovery from mivacurium in adults [29-31] and in children. [32] However, edrophonium is more effective in antagonizing an intense mivacurium block when neostigmine may impede spontaneous recovery. [33-35] When reversal is necessary, edrophonium is preferable to neostigmine, because the latter inhibits pChe [36] to a greater extent. [37] The inhibition probably is responsible both for the impaired recovery from intense block and for the lower neostigmine:edrophonium potency ratio found in the reversal of mivacurium [31] than of other nondepolarizing relaxants. [38] However, it has been shown that the administration of neostigmine during the course of a mivacurium infusion increased the circulating concentrations of the trans-trans and cis-trans stereoisomers of mivacurium [39] and the authors suggested that this might be responsible for the impaired antagonism of the block. However, similar increases were observed after edrophonium, [40] so that this is an unlikely explanation for any difference between neostigmine and edrophonium. In addition, the relationship between plasma concentrations of mivacurium and neuromuscular block have not been compared in this situation.
In conclusion, this randomized double-blind study has shown that, when mivacurium-induced neuromuscular blockade was allowed to recover spontaneously, residual block was not observed in pediatric patients. However, in adults, residual weakness was identified in 6 of 25 patients in whom edrophonium-reversal was replaced with saline. Consequently, it should not be assumed that the neuromuscular blockade produced by mivacurium does not need to be reversed.
Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, El-Sayad HA: The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). ANESTHESIOLOGY 1988; 68:723-32.
Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE: Clinical pharmacology of atracurium besylate (BW 33A): A new non-depolarizing muscle relaxant. Anesth Analg 1982; 61:723-9.
Fisher DM, Miller RD: Neuromuscular effects of vecuronium (ORG NC45) in infants and children during N sub 2 O, halothane anesthesia. ANESTHESIOLOGY 1983; 58:519-23.
Bevan DR, Bevan JC, Donati F: Muscle Relaxants in Clinical Anesthesia. Chicago, Year Book, 1988, p 194.
Suzuki H, Hashimoto Y, Hanaoka K, Amaki Y, Kobayashi T, Yamamura H: A comparison between neuromuscular blocking affects of pipecuronium and vecuronium: A double blind controlled study in collaboration with 5 departments of anesthesiology. MASUI 1994; 43:1583-9.
Dresner DL, Basta SJ, Ali HH, Schwartz AF, Embree PB, Wargin WA, Lai AA, Brady KA, Savarese JJ: Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. Anesth Analg 1990; 1:498-502.
Goudsouzian NG, Alifimoff JK, Eberly C, Smeets R, Griswold J, Miler V, McNulty BF, Savarese JJ: Neuromuscular and cardiovascular effects of mivacurium in children. ANESTHESIOLOGY 1989; 70:237-42.
Goudsouzian NG, Liu LMP, Cote CJ, Gionfriddo M, Rudd GD: Safety and efficacy of atracurium in adolescents and children anesthetized with halothane. ANESTHESIOLOGY 1983; 59:459-62.
Goudsouzian NG, Martyn JJA, Liu LMP, Gionfriddo M: Safety and efficacy of vecuronium in adolescents and children. Anesth Analg 1983; 62:1083-8.
Bevan DR, Bevan JC, Donati F: Muscle Relaxants in Clinical Anesthesia. Chicago, Year Book, 1988, p 360.
Diefenbach C, Mellinghoff H, Lynch J, Buzello W: Mivacurium: Dose-response relationship and administration by repeated injection or infusion. Anesth Analg 1992; 74:420-3.
Rossen RM, Krikorian J, Hancock EW: Ventricular asystole after edrophonium chloride administration. JAMA 1976; 235:1041-2.
King MJ, Milazkiewicz R, Carli F, Deadcock AR: Influence of neostigmine on postoperative vomiting. Br J Anaesth 1988; 61:403-6.
Ding Y, Fredman B, White PF: Use of mivacurium during laparoscopic surgery: Effect of reversal drugs on postoperative recovery. Anesth Analg 1994; 78:450-4.
Viby-Mogensen J, Jorgensen BC, Ording H: Residual curarization in the recovery room. ANESTHESIOLOGY 1979; 50:539-41.
Beemer GH, Rozental P: Postoperative neuromuscular function. Anaesth Intensive Care 1986; 14:41-5.
Bevan DR, Smith CE, Donati F: Postoperative neuromuscular blockade: A comparison between atracurium, vecuronium, and pancuronium. ANESTHESIOLOGY 1988; 69:272-6.
Baxter MRN, Bevan JC, Samuel J, Donati F, Bevan D: Postoperative neuromuscular function in pediatric day-care patients. Anesth Analg 1991; 72:504-8.
Meretoja OA, Gebert R: Postoperative neuromuscular block following atracurium or alcuronium in children. Can J Anaesth 1990; 37:743-6.
Meakin G, Sweet PT, Bevan JC, Bevan DR: Neostigmine and edrophonium as antagonists of pancuronium in infants and children. ANESTHESIOLOGY 1983; 59:316-21.
Fisher DM, Cronnelly R, Miller RD, Sharma S: The neuromuscular pharmacology of neostigmine in infants and children. ANESTHESIOLOGY 1983; 59:220-5.
Fisher DM, Cronnelly R, Sharma M, Miller RD: Clinical pharmacology of edrophonium in infants and children. ANESTHESIOLOGY 1984; 61:428-33.
Ostergaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J: Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade in phenotypically normal patients. Acta Anaesthesiol Scand 1992; 36:702-6.
Ostergaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J: Mivacurium-induced neuron muscular blockade in patients with atypical plasma cholinesterase. Acta Anaesthesiol Scand 1993; 37:314-8.
Petersen RS, Bailey PL, Kalameghan R, Ashwood ER: Prolonged neuromuscular block after mivacurium. Anesth Analg 1993; 76:194-6.
Vassallo SA, Denman W, Goudsouzian NG: Plasma cholinesterase activity and dibucaine number in infants and children. Paediatr Anaesth 1994; 4:313-7.
Pantuck E: Plasma cholinesterase: Gene and variations. Anesth Analg 1993; 77:380-6.
Gill SS, Bevan DR, Donati F: Edrophonium antagonism of atracurium during enflurane anaesthesia. Br J Anaesth 1990; 64:300-5.
Wrigley SR, Jones RM, Harrop-Griffiths AW, Platt MW: Mivacurium chloride: A study to evaluate its use during propofol-nitrous oxide anaesthesia. Anaesthesia 1992; 47:653-7.
Maddineni VR, Mirakhur RK, McCoy EP: Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion. Anaesthesia 1994; 49:946-8.
Naguib M, Abdulatif M, Al-Ghambi A, Hamo I, Nouheid R: Dose-response relationships for edrophonium and neostigmine antagonism of mivacurium-induced neuromuscular block. Br J Anaesth 1993; 71:709-14.
Fonseca J, Chaudry IA, Marin F, Halliday NJ, Radvany T, Bikhazi GB, Foldes FF: Mivacurium block: Spontaneous and neostigmine or edrophonium induced recovery in children. Anesth Analg 1994; 78:S118.
Kao YJ, Le N, Barker SJ: Neostigmine prolongs profound neuromuscular blockade induced by mivacurium in surgical patients. (abstract). ANESTHESIOLOGY 1993; 79:A929.
Abdulatif M: Recovery characteristics after early administration of anticholinesterases during intense mivacurium-induced neuromuscular block. Br J Anaesth 1995; 74:20-5.
Devcic A, Munshi C, Gandhi S: Mivacurium reversal: Edrophonium vs. neostigmine (abstract). ANESTHESIOLOGY 1994; 81:A1067.
Cook DR, Chakravorti S, Brandom BW, Stiller RL: Effects of neostigmine, edrophonium and succinylcholine on the in vitro metabolism of mivacurium: clinical correlates (abstract). ANESTHESIOLOGY 1992; 77:A948.
Mirakhur RK: Edrophonium and plasma cholinesterase activity. Can Anaesth Soc J 1986; 33:588-90.
Smith CE, Donati F, Bevan DR: Dose-response relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade. ANESTHESIOLOGY 1989; 71:37-43.
Szenohradszky J, Lau M, Brown R, Sharma ML, Fisher DM: The effect of neostigmine on twitch tension and muscle relaxant concentration during infusion of mivacurium or vecuronium. ANESTHESIOLOGY 1995; 83:83-7.
Hart PS, Wright PMC, Brown R, Lau M, Sharma ML, Mill RE, Gruenka L, Fisher DM: Edrophonium increases mivacurium concentrations during constant mivacurium infusion, and large doses minimally antagonize paralysis. ANESTHESIOLOGY 1995; 82:912-8.
Table 1. Demographic Data
Image not available
Table 1. Demographic Data
Table 2. Characteristics of Mivacurium Meeting Abstracts Related to Train-of-Four Ratio Measured on Arrival in the Postanesthesia Care Unit in Adults and Children*
Image not available
Table 2. Characteristics of Mivacurium Meeting Abstracts Related to Train-of-Four Ratio Measured on Arrival in the Postanesthesia Care Unit in Adults and Children*
Table 3. Characteristics of the Seven (14%) Adult Patients Who Demonstrated Residual Block (TOF < 0.7) on Arrival in the Postanesthesia Care Unit
Image not available
Table 3. Characteristics of the Seven (14%) Adult Patients Who Demonstrated Residual Block (TOF < 0.7) on Arrival in the Postanesthesia Care Unit